RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

Matan Companies is proud to announce that its premier 44-acre life science and industrial campus fronting I-270 in ...

England has embraced degree apprenticeship as a solution to a wide range of challenges, including high youth unemployment, spiraling student debt and rapid technological change. The programs have been ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. In a recent clinical study update, AstraZeneca has completed a Phase 2a ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. AstraZeneca recently completed a clinical study titled ‘A Multiple Centre, ...

Steve Eisman is a hedge-fund trader best known on Wall Street for successfully betting against the housing market before the recession of 2007-09. His experiences in the lead-up to the financial ...

President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...

BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.Less than half ...

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

AstraZeneca PLC (NASDAQ:AZN), the British pharmaceutical company best known for its COVID-19 drug, was at the center of analyst action on December 9th after a report from TD Cowen.

More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one backdated for November 24 for Daiichi Sankyo’s tenosynovial giant cell ...